GEA introduces the XStream lab homogeniser for cell disruption and scale-up

Published: 26-Aug-2022

To extend the homogenisation process from laboratory to production scale while achieving the same cell-dissolving effect in the manufacturing process of proteins and microorganisms, GEA offers the XStream lab homogeniser

The benchtop unit is designed for laboratory testing and reliably delivers transferable results to industrial production scale.

High-pressure homogenisation is used in the pharmaceutical and biotech industries primarily for cell disruption. GEA homogenisers such as the XStream lab homogenizer can achieve cell disruption of more than 90%, depending on the product.

Applications include vaccines, intravenous emulsions, liposomes, yeast, enzymes and bacteria.

The XStream lab homogeniser is ergonomically and specifically designed for a perfect fit on lab benches. The machine is easy to operate and to control via a PLC and HMI 7'' touchscreen.

Furthermore, the equipment has automatic pressure setting and adjustment, cGMP, CFR21 and GAMP certifications. There is replication and scalability of test results and an overall straightforward validation process.

The XStream lab homogenizer is available as a version for a maximum pressure of 1000 bar (XStream Lab Homogenizer 1000) and for a maximum pressure of 2000 bar (XStream Lab Homogenizer 2000).

Homogenisers stabilise active ingredients and dispersion in liquid pharmaceutical products for improved clinical efficacy, enhanced drug tolerance and reduced dosage. Homogenisation is also used for cell disruption in yeast and bacteria to extract intracellular substances.

Homogenizers enable the release of the inner cell content. The basic process for producing proteins involves first growing the engineered micro-organisms in fermentation bioreactors, in which the microbial cells are provided with all the nutrients and other factors they need to multiply rapidly.

The bacteria are then removed from the bioreactors and subjected to homogenisation, in which the cells are broken open to release their contents.

The recombinant proteins released from the bacteria can then be isolated and purified for the customer, who can use them, for example, as starting material for further manufacturing steps or as active pharmaceutical ingredients that are either already on the market or under development.

You may also like